2026-03-07 05:22:30

if we shift the conversation away from GLP-1 inhibs to potentially better or complementary pathways like amylin or GIP, the reality is the same players still dominate the pipeline. Novo Nordisk and Eli $LLY are still leading most of the meaningful peptide R&D and combination

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes